Publications

At AIDA Oncology, we translate complex tumor biology into clinically validated drug response predictors. Our work focuses on transcriptome-based precision oncology across multiple cancer types, with a particular emphasis on breast cancer.

Taxane

01-06-2026 | 2026 ASCO Annual Meeting I | Abstract

Prediction of pathologic response using a taxane-based gene expression signature in RNA-sequencing data from breast cancer patients receiving neoadjuvant therapy.

Nart, J., Hahn, B., Niklassen, J. H., Jensen, P. B., Buhl, U. H., Buhl, I. K., Berg, T., Ejlertsen, B

01-06-2026 | 2026 ASCO Annual Meeting I | Abstract

Evaluation of a taxane mRNA-based profile in neoadjuvant therapy across I-SPY2 investigational arms

Niklassen, J. H., Nart, J., Hahn, B., Buhl, I. K., Jensen, P. B., Buhl, U. H., Ejlertsen, B., Berg, T., O’Shaughnessy, J.

01-06-2026 | 2026 ASCO Annual Meeting I | Abstract

Taxane and platinum combination as a predictor of pathologic complete response in I-SPY2 by gene expression breast cancer signatures

Niklassen, J. H., Hahn, B., Nart, J., Buhl, I. K., Jensen, P. B., Buhl, U. H., Knudsen, S., Jensen, T., Lassen, U., Ejlertsen, B., O’Shaughnessy, J.

01-06-2025 | 2026 ASCO Annual Meeting I | Abstract

A Machine Learning Model to Accurately Predict Taxane Response in Neoadjuvant Breast Cancer

Berg, T. (1, 2), Jacob Hansen Niklassen: Niklassen, J.H. (3), Bent Ejlertsen: Ejlertsen, B. (1, 2), Beatrice Hahn: Hahn, B. (3), Jan Nart: Nart, J. (3), Peter Buhl Jensen: Jensen, P.B. (3), Ulla Hald Buhl: Buhl, U.H. (3), Ida Kappel Buhl: Buhl, I.K. (3)

Docetaxel & Paclitaxel

10-12-2025 | San Docetaxel and Paclitaxel Antonnio Breast Cancer Synospium I | SABCS Late-breaking abstract

Evaluation of a 113-gene predictor of benefit from neoadjuvant T-AC treatment in an I-SPY2 cohort

J.H. Niklassen, T. Berg, B. Ejlertsen, B. Hahn, J. Nart, P.B. Jensen, U.H. Buhl, I.K. Buhl

20-10-2025 | 2025 ESMO Annual Meeting I | Abstract

Predicting Taxane Response in Danish Breast Cancer Patients

T.D. Christensen, J. Nart, A.S. Buhl Rasmussen, J.H. Niklassen, B. Hahn, B. Ejlertsen, A.S. Knoop, F.O. Bagger, S.G. Sørensen, U.H. Buhl, I. Kappel Buhl, E. van Boven, P.B. Jensen

Epirubicin & Doxorubicin

29-05-2024 | 2024 ASCO Annual Meeting I | Abstract

Predicting epirubicin response in Danish patients with breast cancer.

Buhl, I. K., Nart, J., Papadovasilakis, Z., Sørensen, S., Jensen, P. B., Ejlertsen, B., ... & Tsamardinos, I.

26-05-2019 | 2019 ASCO Annual Meeting I | Abstract

Doxorubicin response prediction in neoadjuvant breast cancer therapy.

Rasmussen, Anna & Christensen, Ib & Knudsen, Steen & Jensen, Peter.

11-08-2018 | Breast Cancer Research and Treatment | Article

Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study.

Buhl, A.S.K., Christensen, T.D., Christensen, I.J. et al.

30-05-2017 | 2017 ASCO Annual Meeting I | Abstract

Retrospective-prospective blinded evaluation predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort.

Rasmussen, Anna & Christensen, Troels & Christensen, Ib & Nelausen, Knud & Balslev, Eva & Knoop, Ann & Brix, Eva & Svensson, Else & Glavicic, Vesna & Luczak, Adam & Langkjer, Sven & Linnet, Soeren & Jakobsen, Erik & Bogovic, Jurij & Ejlertsen, Bent & Rasmussen, Annie & Hansen, Anker & Knudsen, Steen & Nielsen, Dorte & Jensen, Peter.

Platinum

30- | Pharmacogenomics | Publication

A drug response predictor to guide treatment for breast cancer.

Hahn, B., Dafni, U., Nart, J., Niklassen, J. H., Buhl, U. H., Buhl, I. K., Knudsen, S., Jensen, T., Tsamtsouri, L., Kammler, R., Danson, S., O'Brien, M. E. R., Finn, S., Jensen, P. B., Hirsch, F. R., Stahel, R. A., Peters, S.

Breast Cancer

20-04-2019 | Pharmacogenomics | Publication

A drug response predictor to guide treatment for breast cancer.

Buhl, I. K., Jensen, P. B., Kappel Buhl, A. S., & Knudsen, S.